News

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models Strengthens position as the leading independent provider of physiologically-relevant in vitro retinal models for ophthalmology drug [...]

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design Cambridge, UK, [...]

Enhancing patient treatment experience and care with a new self-administered solution for vaginal therapeutics Versatile platform technology developed from a safe, award-winning, FDA-cleared medical device Strategic collaboration supporting the continued [...]

Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional and AI-based drug discovery Enables primary screening with high-resolution binding First order and shipment slated for Q1 will [...]

Automated workflow to be highlighted at SLAS 2026, 7-11 February, Boston Collaboration combines precision liquid handling technology with Transcreener ADP2 fluorescence polarization assay for screening of VPS4B ATPase inhibitors Cambridge, [...]

Access to automated instrumentation will enhance precision testing and improve analytical efficiency, streamlining criminal identification Hamburg, DE, 09 February 2026 – Eppendorf, a leading international life science company that develops, [...]

Collaboration heralds new era of assay development in drug discovery London, UK, 09 February 2026: Synthace, the leader in software and services for assay development, today announced a collaboration with [...]

HERCULES, Calif. — February 6 2026 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced it has received validation [...]

Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue Sheffield, UK, 05 February 2026: SynGenSys, a biotechnology company designing [...]

Expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses Responds to growing demand for scalable, patient-relevant human models [...]

Expansion accelerates the development of its non-invasive cancer diagnostic solutions Manchester, UK – 27 January 2026 – Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities [...]

Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities In-person [...]